Conversely, the upregulation of miR-199a reduced the IBS visceral pain through the inhibition of the TRPV1 signaling, indicating that miR-199a precursors might be clinically tested to the treatment of inflammatory visceral pain and in particular IBS [45]. The gene discussed is TRPV1; the disease is irritable bowel syndrome.